Previous 10 | Next 10 |
Shares of BioXcel Therapeutics (NASDAQ: BTAI) , a clinical-stage biotechnology company, fell hard this week as shareholders responded to a secondary share offering. Since the market closed last Friday, the biotech stock has lost around 16.8% of its value. On June 23, 2021, B...
BioXcel Therapeutics ([[BTAI]] -15.4%) has priced public offering of 3.155M common shares at $31.70 per share, for estimated gross proceeds of ~$100M.Underwriters' over-allotment is an additional 473,250 shares, granted by a related party stockholder, BioXcel LLC.The company will not rec...
NEW HAVEN, Conn., June 23, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of an underwritten public offering of 3,155,000 shares of common stock at a public...
Gemini Therapeutics (GMTX) -31% after initial data from mid-stage GEM103 AMD study.Second Sight Medical Products (EYES) -18% after secures $50M capital via equity raiseTorchlight Energy Resources (TRCH) -17%.Alfi (ALF) -16% stock pulls back from buyback-fueled ra...
BioXcel Therapeutics (BTAI) announces that it has commenced an underwritten public offering of $100M.Expects to grant the underwriters a 30-day option to purchase up to $15M of additional shares.Intends to use net proceeds to fund ongoing clinical trials, commercialization preparation and for...
NEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today...
NEW HAVEN, Conn., June 18, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today ...
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
BioXcel has a January 5 PDUFA for its lead candidate. The stock is down strongly. Strong data and market potential for lead indication makes the drop attractive. For further details see: BioXcel: Upcoming PDUFA Makes Recent Drop Attractive
NEW HAVEN, Conn., May 26, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today a...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...